Chimera Bio

Chimera Bioengineering is a South San Francisco-based biotechnology company developing advanced CAR-T cell therapies designed to treat solid tumors. The company's core technology, the Goldilocks platform, uses RNA-based regulatory systems to provide precise control over the potency and persistence of engineered T cells. This approach aims to mitigate the toxicities often associated with systemic immunotherapy while enhancing the ability of CAR-T cells to penetrate and survive within the immunosuppressive microenvironment of solid tumors. By creating programmable and tunable immunotherapies, Chimera Bioengineering aims to provide safer and more effective treatment options for patients with hard-to-treat malignancies.